Literature DB >> 10468067

Co-expression of vascular endothelial growth factor and thymidine phosphorylase in endometrial cancer.

R Fujiwaki1, K Hata, K Iida, Y Maede, Y Watanabe, M Koike, K Miyazaki.   

Abstract

OBJECTIVE: To examine expression of vascular endothelial growth factor (VEGF) and thymidine phosphorylase (TP) together with microvessel count in endometrial cancer, and to investigate the relationship with clinicopathological and biological factors.
METHODS: VEGF expression, TP expression, the microvessel count (factor VIII-related antigen positive cells), bcl-2 expression, proliferating cell nuclear antigen (PCNA) index, and p53 expression were determined in 50 resected endometrial cancer specimens, using immunohistochemistry. The relationship between VEGF and TP expression and correlation between expression and microvessel count were also given attention. These 3 factors were analyzed with regard to clinicopathological factors, bcl-2 expression, PCNA index, and p53 expression.
RESULTS: Staining status of VEGF and TP was identical in 37 (74%) of 50 tumors, the correlation being statistically significant (p < 0.01). Combined analysis of VEGF and TP status showed that tumors which were VEGF-positive and/or TP-positive had a significantly higher microvessel count than did tumors which were both VEGF-negative and TP-negative (p < 0.001 and p < 0.05, respectively). TP expression correlated with bcl-2 expression, and VEGF expression inversely correlated with the PCNA index. Although clinical stage (p < 0.01), PCNA index (p < 0.01), and p53 expression (p < 0.01) significantly correlated with disease-free survival, neither VEGF/TP expression nor microvessel count contributed to prognostic estimates.
CONCLUSIONS: VEGF and TP may cooperatively promote angiogenesis in endometrial cancer, but these expressions may have limited additional prognostic value.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10468067

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells.

Authors:  T Fujisawa; J Watanabe; Y Kamata; M Hamano; H Hata; H Kuramoto
Journal:  Hum Cell       Date:  2003-03       Impact factor: 4.174

2.  Expression of cyclooxygenase-2 and inducible nitric oxide synthase correlates with tumor angiogenesis in endometrial carcinoma.

Authors:  Wei Li; Ru-jun Xu; Li-hui Jiang; Jingfeng Shi; Xiang Long; Bei Fan
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

3.  A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Robert L Coleman; Michael W Sill; Heather A Lankes; Amanda Nickles Fader; Neil J Finkler; James S Hoffman; Peter G Rose; Gregory P Sutton; Charles W Drescher; D Scott McMeekin; Wei Hu; Michael Deavers; Andrew K Godwin; R Katherine Alpaugh; Anil K Sood
Journal:  Gynecol Oncol       Date:  2012-08-23       Impact factor: 5.482

4.  Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.

Authors:  Elvira Montero; Carmen Abreu; Paola Tonino
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.553

Review 5.  The dual role of thymidine phosphorylase in cancer development and chemotherapy.

Authors:  Annelies Bronckaers; Federico Gago; Jan Balzarini; Sandra Liekens
Journal:  Med Res Rev       Date:  2009-11       Impact factor: 12.944

6.  Association between RCAS1 expression and clinical outcome in uterine endometrial cancer.

Authors:  K Sonoda; S Miyamoto; T Hirakawa; T Kaku; M Nakashima; T Watanabe; K Akazawa; T Fujita; H Nakano
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.